1 / 13

Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study

Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study. I. Migdalis a , A. Efthimiadis b , St. Pappas c , D. Alexopoulos d , F. Vlasserou e and D. P. Mikhailidis f a 2nd Department of Internal Medicine, NIMTS General Hospital, Athens, Greece

judith
Download Presentation

Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical experience withezetimibe/simvastatin in aMediterranean populationThe SETTLE Study I. Migdalisa, A. Efthimiadisb, St. Pappasc, D. Alexopoulosd , F. Vlasseroue and D. P. Mikhailidisf a2nd Department of Internal Medicine, NIMTS General Hospital, Athens, Greece bCardiology Department, Hippokration General Hospital, Thessaloniki, Greece c3rd Department of Internal Medicine, NIKAIA General Hospital, Athens, Greece dCardiology Department, University Hospital of Rion, Patras, Athens, Greece eMedical Department, VIANEX Pharmaceuticals SA, Athens, Greece fDepartment of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Campus, University College

  2. SETTLE StudySimvastatin Ezetimibe Therapy to Target Lipids Elevation Background Elevated plasma low-density lipoprotein cholesterol (LDL-C) is a pivotal risk factor in the development of atherosclerotic coronary heart disease (CHD). Optimal management of plasma LDL-C levels is the primary goal of therapeutic intervention in patients at risk of coronary events.

  3. SETTLE Study Objective • In hypercholesterolemic patients with LDL-Cout of goal, despite prior use of statin monotherapy, to evaluate the efficacy of switching to ezetimibe/ simvastatin (EZE/SIMVA) 10/20 mg or 10/40 mg. • To record CHD risk factors of hypercholesterolemic patients in Greece and observe the routine clinical practice of the use of ezetimibe / simvastatin

  4. SETTLE Study: Patients The study was conducted at 100 sites all over Greece and included 1514 patients. Male or female mean age: 60 yrs. LDL-Cout of goal, according to physician’s evaluation at screening visit All patients were previously treated with statin monotherapy male female 46.6% 53.4%

  5. PATIENTS CO-MORBIDITIES / RISK FACTORS % Diabetes Mellitus 29.9% Hypertension 61.2% Obesity 25.6% Angina 10.5% Myocardial infarction 12.4% Revascularization procedure 14.1% Stroke or peripheral arteriopathy 6.8% Congestive heart failure 2.9% Smoking 31.1% Ex-smoking 15.7% SETTLE Study: Patients • The number of patients who had three risk factors or at least one CHD equivalent medical condition was 889 (58%)

  6. Primary % patients achieving LDL-C at study endpoint (post therapy, Visit 2) Secondary Mean % change in LDL-C, TC, TG, HDL-C at study endpoint (post therapy) Tolerability (monitoring of adverse experiences) SETTLE Study: Efficacy Endpoints

  7. Screening Week 0 Week 8 No Washout 2 Visit Visit1 SETTLE Study: Study Design • This was a Phase IV, multi-center, observational study Patients prior statin monotherapy: Eze/Simva 10/20 mg/day (n=1074) Simvastatin 20 or 40 mg Atorvastatin 10 or 20 mg Eze/Simva 10/40 mg/day (n=440) Pravastatin 40 mg Fluvastatin 80 mg Rosuvastatin 5 mg

  8. SETTLE Study: Efficacy Parameters at Study Endpoint

  9. 56.8 mg/dl 37.1mg/dl 66.7mg/dl 3mg/dl LDL-C HDL-C TC TG SETTLE Study: Efficacy Parameters at Study Endpoint Changes in Lipid variables during the study (mean of absolute values, mg/dl)

  10. AtGoal Not at Goal 26.2% (n=397) (n=1117) 73.8% SETTLE Study: % of Patients Reaching LDL-C Goals at Study Endpoint

  11. Adverse experiences • In 18 patients,23 adverse experiences were reported(1.2%) • Most of them were mild and expected (dizziness, rash, myalgia, GI symptoms, CPK increase in 2 patients, aminotransferase increase in 3 patients) • There was one serious AE, which was NOT related to the study treatment. • There was no difference in patients, at or NOT at goal. • There was statistical difference in patients administered INEGY 10/20 or 10/40 mg • There was no difference in patients more or less than 65 years old.

  12. SETTLE Study: Summary of Results • In patients taking a stable dose of statin monotherapy, switching to EZE/SIMVA 10/20 mg or 10/40 mg resulted in: • Significantly greater reductions in LDL-C, TC, TG and non-HDL-C, (p£0.001) • More patients achieving LDL-C goal, as this was determined by their attending physician (p£0.001) • In the routine clinical care setting, the safety/tolerability profile of EZE/SIMVA was favorable • The present study showed that switching from statin monotherapy to EZE/SIMVA 10/20 mg or 10/40 mg provides greater reductions in LDL-C, resulting in clinically significant increases in the proportion of high-risk patients achieving LDL-C goals.

  13. SETTLE Study: Conclusion • In our Mediterranean population, the combination of EZE / SIMVA appears to be an appropriate and safe treatment option for patients who cannot achieve the LDL-C target with statin monotherapy

More Related